Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year ...
Teva is the leading generic drug manufacturer in the world. By our estimate, roughly 70% of its total sales are derived from generics and off-patent branded drugs, and the company continues to ...
Generic Drugs Drive Sales in TEVA’s United States Unit Sales in the United States segment (previously the North America segment) were $2.22 billion, up 17% year over year, driven by higher sales ...